JPWO2023143365A5 - - Google Patents
Info
- Publication number
- JPWO2023143365A5 JPWO2023143365A5 JP2024544709A JP2024544709A JPWO2023143365A5 JP WO2023143365 A5 JPWO2023143365 A5 JP WO2023143365A5 JP 2024544709 A JP2024544709 A JP 2024544709A JP 2024544709 A JP2024544709 A JP 2024544709A JP WO2023143365 A5 JPWO2023143365 A5 JP WO2023143365A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- drug conjugate
- her3 antibody
- pharmaceutically acceptable
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210107800.8 | 2022-01-28 | ||
| CN202210107800 | 2022-01-28 | ||
| CN202310015113 | 2023-01-05 | ||
| CN202310015113.8 | 2023-01-05 | ||
| PCT/CN2023/073130 WO2023143365A1 (zh) | 2022-01-28 | 2023-01-19 | Her3抗体药物偶联物及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025503214A JP2025503214A (ja) | 2025-01-30 |
| JP2025503214A5 JP2025503214A5 (https=) | 2026-01-26 |
| JPWO2023143365A5 true JPWO2023143365A5 (https=) | 2026-01-26 |
Family
ID=87470787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544709A Pending JP2025503214A (ja) | 2022-01-28 | 2023-01-19 | Ｈｅｒ３抗体－薬物結合体及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250295802A1 (https=) |
| EP (1) | EP4470570A1 (https=) |
| JP (1) | JP2025503214A (https=) |
| KR (1) | KR20240157659A (https=) |
| CN (1) | CN118434453A (https=) |
| AU (1) | AU2023213783A1 (https=) |
| IL (1) | IL314567A (https=) |
| MX (1) | MX2024009159A (https=) |
| TW (1) | TW202341984A (https=) |
| WO (1) | WO2023143365A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20252282A1 (es) * | 2022-10-09 | 2025-09-18 | Lanova Medicines Ltd | Compuestos, composiciones y metodos |
| IL320634A (en) * | 2022-11-04 | 2025-07-01 | Alx Oncology Inc | EXATECAN derivatives and antibody-drug conjugates |
| EP4692091A1 (en) * | 2023-04-07 | 2026-02-11 | Changchun Genescience Pharmaceutical Co., Ltd. | Camptothecin derivative, and pharmaceutical composition, preparation method therefor and use thereof |
| WO2024248123A1 (ja) | 2023-06-02 | 2024-12-05 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ |
| WO2025031286A1 (zh) * | 2023-08-04 | 2025-02-13 | 映恩生物制药（苏州）有限公司 | 抗体药物偶联物的识别抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| KR102399277B1 (ko) * | 2014-04-10 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| KR20210062005A (ko) * | 2018-09-20 | 2021-05-28 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘쥬게이트 투여에 의한 her3 변이암의 치료 |
| WO2020063676A1 (zh) * | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| MX2023003778A (es) * | 2020-09-30 | 2023-04-26 | Duality Biologics Suzhou Co Ltd | Compuesto antitumoral, metodo de preparacion y uso del mismo. |
| AU2022293634A1 (en) * | 2021-06-15 | 2024-01-18 | Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. | Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof |
-
2023
- 2023-01-19 AU AU2023213783A patent/AU2023213783A1/en active Pending
- 2023-01-19 IL IL314567A patent/IL314567A/en unknown
- 2023-01-19 CN CN202380013747.8A patent/CN118434453A/zh active Pending
- 2023-01-19 JP JP2024544709A patent/JP2025503214A/ja active Pending
- 2023-01-19 KR KR1020247027679A patent/KR20240157659A/ko active Pending
- 2023-01-19 EP EP23746246.0A patent/EP4470570A1/en active Pending
- 2023-01-19 TW TW112102804A patent/TW202341984A/zh unknown
- 2023-01-19 MX MX2024009159A patent/MX2024009159A/es unknown
- 2023-01-19 US US18/833,846 patent/US20250295802A1/en active Pending
- 2023-01-19 WO PCT/CN2023/073130 patent/WO2023143365A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106459200B (zh) | 抗-egfr抗体及抗体药物偶联物 | |
| JP7458981B2 (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP2020019787A5 (https=) | ||
| JP2012522513A5 (https=) | ||
| JP2012522512A5 (https=) | ||
| JP2020509027A5 (https=) | ||
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| JP2018534933A5 (https=) | ||
| JP2014139173A5 (https=) | ||
| JP2017522861A5 (https=) | ||
| EP4470570A1 (en) | Her3 antibody-drug conjugate and use thereof | |
| JP2019512262A5 (https=) | ||
| JPWO2022022508A5 (https=) | ||
| JP2016540826A5 (https=) | ||
| US20250049938A1 (en) | Antibody-drug conjugate and use thereof | |
| JPWO2023143365A5 (https=) | ||
| RU2016119491A (ru) | Конъюгаты антитела к efna4 с лекарственным средством | |
| JPWO2023186015A5 (https=) | ||
| CN119053607A (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| JPWO2024110905A5 (https=) | ||
| JPWO2023051621A5 (https=) | ||
| RU2025134256A (ru) | Конъюгат антитела к pdl1 и лекарственного средства и применение | |
| RU2025131232A (ru) | Конъюгат антитело анти-cdh6-лекарственное средство и его применение | |
| RU2025136351A (ru) | Способ лечения солидных опухолей с помощью конъюгата антитело-лекарственное средство, нацеленного на клаудин 18.2 | |
| CN121285392A (zh) | 一种抗pdl1抗体-药物偶联物及应用 |